Goodwin Procter LLP advised HiFiBiO on the deal.
HiFiBiO announced its oversubscribed $75 million Series D financing round.
HiFiBiO is a multinational biotechnology company with unique expertise in immune modulation and drug intelligent science.
The funding was led by the new investor Mirae Asset Financial Group. B Capital Group, Sherpa, Maison Capital, Trinity Innovation Fund, Grand Mount, and HKSTP Venture Fund also participated in this round. The existing shareholders IDG, Sequoia, Legend Star, and Hengxu continued to invest.
HiFiBiO Therapeutics will use the proceeds from the financing to advance two lead antibody oncology assets into Phase I clinical trials — HFB200301, a novel anti-TNFR2 antibody and HFB301001, a differentiated second generation anti-OX-40 antibody. The company will leverage its Drug Intelligent Science (DIS™) platform which combines deep-rooted biological expertise, single-cell science, and advanced data intelligence tools to enhance the probability of success of these two trials as well as future trials. Additionally, the company will continue to advance multiple pipeline programs through discovery and clinical development.
The Goodwin team was led by Wenseng “Wendy” Pan (Picture) and included Kevin Guan, Julie Tibbets, and Elizabeth Mulkey.
Law Firms: Goodwin Procter;
Clients: HiFiBiO Therapeutics ;